A surgical site infection (SSI) is one of the most common complications of extremity surgery, especially when implants are involved. The infection rate ranges from 1.3% to 10% in hip and knee procedures (Agodi et al. [@CIT0001], De Jong et al. [@CIT0016]) to 12% to 25% (Backes et al. [@CIT0004], Feilmeier et al. [@CIT0017], Wiewiorski et al. [@CIT0035]) in foot and ankle surgery. Antibiotic prophylaxis is widely used and has been shown to lower infection rates in closed fracture surgery (Burnett et al. [@CIT0012], Boxma et al. [@CIT0007]), as well as in primary arthroplasty (AlBuhairan et al. [@CIT0002], Voigt et al. [@CIT0033]). Because of their broad-spectrum effect on methicillin-sensitive staphylococci and streptococci and relatively low costs, first-generation cephalosporins (e.g., cefazolin, cephradine, or cephalexin) are the recommended prophylactics in orthopedic/trauma surgery (Mangram et al. [@CIT0022], Bauer et al. [@CIT0005]). However, there is limited evidence to support dosage recommendations in this field. The studies that form the foundation for the dosage, as mentioned in several international guidelines on surgical prophylaxis, do not include patients undergoing fracture/implant surgery (Bratzler et al. [@CIT0008], Moine and Fish [@CIT0025], Brill et al. [@CIT0009]).

For prophylactic antibiotics to prevent infections it is necessary to achieve concentrations that exceed the minimum inhibitory concentration (MIC) of the targeted pathogen for at least the time between incision and closure of the wound (Burke [@CIT0011]). The MIC is the serum concentration that an antibiotic should exceed to inhibit a certain pathogen (e.g., MIC of cefazolin for *S. aureus* is 0.5--2 µg/L, meaning that a cefazolin concentration in serum of 0.5--2 ug/L is necessary for adequate inhibition of *S. aureus*). Because drugs are not evenly distributed through the body, it is important to know that an antibiotic achieves sufficient concentrations not only in serum but also at the target site (location of surgery) (Müller et al. [@CIT0027]). Data on target-site concentrations of cefazolin during orthopedic surgery of the extremities could provide us with the necessary information to assess and improve the efficacy of prophylactic cefazolin.

The aim of this systematic review was to answer the following questions:What are the target-site concentrations of cefazolin in the extremities during orthopedic surgery?What is the influence of location of the target site and dose of cefazolin on the target site concentration?

Methods {#s0001}
=======

Search strategy and criteria {#s0002}
----------------------------

This meta-analysis and systematic review was performed according to the PRISMA statement (Moher et al. [@CIT0024]) and registered in PROSPERO (no. CRD42018093697). A search was performed in MedLine (PubMed), EMBASE (Ovid), and the Cochrane Library. A clinical librarian was consulted on the search strategy. The search included the following keywords: "cephalosporins," "orthopedic," "extremity," "surgical procedures," and "pharmacokinetics" (see [Supplementary data](https://doi.org/10.1080/17453674.2019.1577014)). The last search was run on January 15, 2018. In addition to the databases, bibliographies were checked for additional articles.

Eligible for inclusion were randomized controlled trials or prospective cohort studies investigating "target site" antibiotic concentrations in human, adult subjects who received prophylactic cefazolin in a single, intravenously administered dose before orthopedic/trauma surgery of the extremity. "Target site" concentrations were defined as concentrations measured in soft tissue, bone, synovia, or wound/drain fluid at or near the site of surgery. To be able to compare dosages, we chose to limit the type of administered prophylaxis to cefazolin only, the most widely studied first-generation cephalosporin. No publication date or language restrictions were imposed.

Study selection {#s0003}
---------------

All identified studies were screened for relevance based on title and abstract by 2 reviewers (TS and FS). The remaining studies were independently screened for eligibility based on full-text reading by the same reviewers and were included if none of the exclusion criteria were met. Studies were excluded based on intervention (cephalosporin that was not cefazolin), study design (reviews or articles only available as abstract), population (when included patients received therapeutic antibiotics up to a week before surgery or had peripheral vascular disease), and outcome (solely serum concentrations measured). Conflicts were discussed until consensus was reached.

The literature search identified 825 articles, of which 626 were assessed for eligibility and a final number of 14 studies were included in the systematic review after full text screening ([Figure 1](#F0001){ref-type="fig"}, [Table 1](#t0001){ref-type="table"}). 5 studies were also included in the meta-analysis (3 in the comparison of different target sites, 1 in the comparison of different cefazolin dosages, 1 in both).

![Flow diagram of included studies.](IORT_A_1577014_F0001_C){#F0001}

###### 

Study characteristics. Characteristics are reported for intervention groups (patients receiving cefazolin i.v. only) unless otherwise reported

  A    B                       C     D     E                       F                        G                    H            I             J           K             L                  M
  ---- ----------------------- ----- ----- ----------------------- ------------------------ -------------------- ------------ ------------- ----------- ------------- ------------------ ----------
  1    Angthong ([@CIT0003])   PC    18    C 1 g iv (12)           --                       70 (5)               25           61 (8)        TKA (18)    Yes           \< TQ / incision   30
                                           C 2 g iv (6)                                     68 (3)               17           62 (8)                                                      
  2    Bryan ([@CIT0010])      DB    97    C 1 g iv (48)           Cefamandole 2 g iv       59 (12)              46                         THA (37)/   NR            30--60 min         NR
                               RCT                                 \(49\)                                                                   TKA (11)                  \< anesthesia       
  3    Cunha ([@CIT0013])      PC    71    C 1 g iv (?)            Cephradine 1 g iv (?)    NR                   NR           NR            THA         No                               NR
                                                                   Cephalothin 1 g iv (?)                                                                                                 
  4    Cunha ([@CIT0014])      PC    35    C 1 g iv (13)           Cephradine 1 g iv (?)    \[61--88\]           NR           NR            TKA         Yes           10--225 min        0.5
                                                                                                                                                                      \< bone removal     
  5    Deacon ([@CIT0015])     PC    25    C 1 g iv (25)           --                       \< 55                NR           NR            Bunion-     Yes           60 min \< TQ       0.5--1.0
                                                                                                                                            ectomy                                        
  6    Friedman ([@CIT0018])   RCT   24    C 1 g                   --                                            52                         TKA         Yes           Until 1, 2,        1
                                           1 min \< TQ (8)                                  67 (8)                            94 (18)                                 or 5 min \< TQ      
                                           2 min \< TQ (8)                                  63 (10)                           98 (22)                                                     
                                           5 min \< TQ (8)                                  60 (8)                            90 (25)                                                     
  7    Miller ([@CIT0023])     PC    15    C 1 g iv (7)            Cefazolin 1 g iv         49                   57           NR            Shoulder    No            20 min             NR
                                                                   \+ regional (8)          \[29--77\]                                      surgery                   \< incision         
                                                                                            *51 (14)*                                                                                     
  8    Parsons ([@CIT0028])    PC    7     C 4 g iv (7)            --                       61 (1.3)             57           65 (5)        THA         No            Immediately        0.25--4
                                                                                                                                                                      \< anesthesia       
  9    Polk ([@CIT0030])       PC    20    C 10 mg/kg              Cefazolin 10 mg/kg       \[27--82\]           65           \[51--83\]    THA         No            Shortly after      NR
                               SR          bolus (9)               infusion (11)                                                                                      anesthesia          
  10   Sharareh ([@CIT0031])   PC    34    C 1 g/2 g               --                       67                   44           83            THA (12)/   Yes **^d^**   \< 60 min to       2
                                           \< 70 kg/                                        \[38--86\]                        \[50--125\]   TKA (22)                  incision / \< TQ    
                                           \> 70 kg (31) **^a^**                            *64 (12)*                         *85 (19)*                                                   
  11   Sørensen ([@CIT0032])   PC    20    C 1 g iv (1) **^b^**    Erythromycin (8)         75                   40 **^c^**   NR            Fixation    No            \< surgery         0.5--3
                                                                   Methicillin (6)          \[48--92\] **^c^**                              femur                                         
                                                                                            *73 (11)*                                       fracture                                      
  12   Williams ([@CIT0036])   PC    125   C 1 g iv (17)           Cephalothin 0.5 g (38)   65                   NR           NR            THA (13)/   Yes **^d^**   30 min \< TQ       0.5--7
                                           C 2 g iv (6)            Cefamandole 2 g (13)     \[13--91\] **^c^**                              TKA (10)                                      
                                                                   Cefoxitin 0.5 g (37)     59 (13)                                                                                       
                                                                   Ceforanide 0.5 g (14)                                                                                                  
  13   Yamada ([@CIT0037])     PC    43    C 2 g iv (43)           --                       75 (8)               16           55 (8)        THA (16)/   Yes **^d^**   \< TQ /incision    1--100
                                                                                                                                            TKA (27)                                      
  14   Young ([@CIT0038])      RCT   22    C 1 g iv (11)           Cefazolin 1 g io (11)    65                   36           BMI 29        TKA         Yes           10--30 min \< TQ   0.5--100
                                                                                            \[48--83\]                        \[23--35\]                                                  
                                                                                            *65 (10)*                                                                                     

AReference number

BFirst author (year)

CStudy design

DB = Double-blind

PC = Prospective cohort

RCT = Randomized controlled trial

SR = Semi-randomized

DTotal number

EIntervention (n)

C = cefazolin

**^a^**3 patients did not receive cefazolin because of allergy, 4 received 1 g, 27 received 2g.

**^b^**6 patients received cefazolin, 3 excluded because of receiving \> 1 dose, 2 no detectable levels.

FComparison (n)

io = intra-osseously administered (ref [@CIT0014])

GMean age (SD)

When only median \[range\] are reported, values were transformed into estimated mean and standard deviation by using the calculations

from Hozo et al. ([@CIT0021]), estimations are given in italics.

**^c^**For all patients, not just intervention group.

HMale sex (%)

IWeight

See G for values in italics.

JType of surgery (n)

KTourniquet use

**^d^**in TKA

LTiming of antibiotic administration

\< = before

TQ = tourniquet

MMIC reported (µg/mL)

Data collection {#s0004}
---------------

Data were extracted using a customized extraction sheet (based on the Cochrane data extraction template), which was pilot-tested on 5 articles randomly selected from the included articles and adjusted accordingly. One reviewer (FS) extracted the data and the other reviewer (TS) verified it. Duplicate publications were filtered out by juxtaposing author names and carefully reviewing study designs and treatment combinations. In the case of multiple publications on one trial, all published information was combined to ensure comprehensiveness of data. Collected information included (1) study characteristics (study design, number of patients included, in/exclusion criteria, and year published), (2) patient characteristics (sex, age, weight, type of procedure, given demographic or disease specifics), (3) type of intervention(s) (dose, timing of administration, comparative), (4) outcome (site of measurement, timing of measurement, unit presented as, type of analysis, results).

Study quality {#s0005}
-------------

Studies were screened for quality and risk of bias using the Newcastle--Ottawa Scale (NOS), designed to assess the quality of nonrandomized cohort studies (Wells et al. [@CIT0034]). Using this scale studies were judged on 9 items within 3 domains (selection, comparability, and outcome) as either good, poor, or unclear, a "good" score counting as one point, with a maximum of 9 points. The rating sheet was adjusted to this review using topic-specific rating criteria (shown in Appendix). Quality screening was performed by one reviewer (FS) and subsequently checked by another reviewer (TS).

Due to heterogeneity of location of measurements, cefazolin dosages and measurement methods, assessment of publication bias---using for example a funnel plot---was not possible.

Statistics {#s0006}
----------

All statistical analyses were performed using Review Manager (RevMan, Version 5.3, the Nordic Cochrane Centre, Copenhagen, the Cochrane Collaboration, 2014). Mean target site antibiotic concentrations were compared between different locations of the target site and between different dosages of cefazolin. To compare these groups, while taking the heterogeneity between studies into account, only studies describing 2 different doses/measuring sites were included in the meta-analysis. Only concentrations measured in bone were included for meta-analysis, since soft tissue samples were not comparable (different locations). Antibiotic concentrations were expressed as weighted mean difference and the corresponding 95% confidence interval (CI). Statistical analyses were performed using a random-effects model, considering the heterogeneity of included trials (Borenstein et al. [@CIT0006]). The I2 was used as a measure for consistency of data. To incorporate the heterogeneity in the estimation of difference in concentrations between hip and knee, a 95% prediction interval (PI) was also computed. Where the CI only represents the average of study effects, the PI presents the range of expected results for 95% of similar studies that might be conducted in the future (Higgins et al. [@CIT0020]). However, as Partlett and Riley ([@CIT0029]) recently concluded, the PI performs best when heterogeneity is high but when there is also a minimum of 5 included studies. With a smaller amount of studies, the PI tends to be too wide, and should not be interpreted as true effect. Statistical significance was defined as p \< 0.05.

Results {#s0007}
=======

Included trials were mostly prospective cohorts (1, 3--5, 7--13, number of refs refers to numbers given in [Table 1](#t0001){ref-type="table"}), except for 3 randomized controlled trials (2, 6, 14). Most studies included patients undergoing elective total hip replacement (n = 3) (3, 8, 9), total knee replacement (n = 4) (1, 4, 6, 14) or both (n = 5) (2, 4, 10, 12, 13) (of which ref no. 4 compared their results in the knee with results in the hip from a previously reported trial (3) in their most recent article) and 1 each included patients with a femur fracture (11), shoulder surgery (7), or bunionectomy (5). [Table 2](#t0002){ref-type="table"} gives an overview of the different target sites and given dose of cefazolin described by each study.

###### 

Cefazolin dose and site of measurement of included studies

  Site       Dose    Reference
  ---------- ------- ---------------------------------------------------------
  Hip        1 g     Bryan et al. ([@CIT0010])
                     Cunha et al. ([@CIT0013])
                     Sharareh et al. ([@CIT0031])
                     Sorensen et al. (1978)
                     Williams et al. ([@CIT0036])
             2 g     Sharareh et al. ([@CIT0031])
                     Williams et al. ([@CIT0036])
                     Yamada et al. ([@CIT0037])
             Other   Parsons et al. ([@CIT0028]), 4 g cefazolin
                     Polk et al. ([@CIT0030]), 10 mg/kg (mean: 684 (108) mg)
  Knee       1 g     Angthong et al. ([@CIT0003])
                     Bryan et al. ([@CIT0010])
                     Cunha et al. ([@CIT0014])
                     Friedman et al. ([@CIT0018])
                     Sharareh et al. ([@CIT0031])
                     Williams et al. ([@CIT0036])
                     Young et al. ([@CIT0038])
             2 g     Angthong et al. ([@CIT0003]
                     Sharareh et al. ([@CIT0031])
                     Williams et al. ([@CIT0036])
                     Yamada et al. ([@CIT0037])
  Foot       1 g     Deacon et al. ([@CIT0015])
  Shoulder   1 g     Miller et al. ([@CIT0023])

All studies reported target site antibiotic concentrations in bone and some also measured concentrations in soft tissue (n = 4) (6--8, 14) or synovial fluid (n = 1) (4). Target site concentrations were reported as a mean value in 10 studies (1, 2, 5, 7--10, 12--14), as mean peak value in 2 studies (3, 4), as separate values per patient in one study (11), and as percentage of patients with values above the MIC in 2 studies (6, 10). Due to the heterogeneity of included studies regarding cefazolin doses, sampling, and analysis methods, the majority of data could not be pooled.

Quality assessment {#s0008}
------------------

Although a minimal score on the NOS suggesting good quality has not been established, the overall risk of bias in the included studies seemed high, with only 5 studies scoring 5 or more out of 9 points on the NOS (Wells et al. [@CIT0034]). The studies used in meta-analysis scored relatively high with 2 studies scoring seven stars and 1 each scoring 6, 5, and 4 points ([Figure 2](#F0002){ref-type="fig"}, see [Supplementary data](https://doi.org/10.1080/17453674.2019.1577014)).

![Risk of bias analysis, according to Newcastle--Ottawa Scale (NOS) (Wells et al[@CIT0034]).\
+: low risk of bias/good quality,\
--: high risk of bias/poor quality,\
?: unknown risk of bias/unclear or not applicable (e.g., comparability of cohorts in studies where only one group received intravenously administered cefazolin).\
A green "+" matches with a star on the NOS.](IORT_A_1577014_F0002_C){#F0002}

Target-site concentrations {#s0009}
--------------------------

### *Bone* concentrations {#s0010}

Overall, target-site antibiotic concentrations in the bone ranged from 0.64 µg/g to 88 µg/g, but the variation of concentrations between different administered dosages of cefazolin and location of measurement was quite large. All of the 10 studies reporting a MIC ([Table 1](#t0001){ref-type="table"}) reported mean target site concentrations higher than the minimum concentration for *S. aureus* (0.5--2 µg/mL). However, most studies also described MICs for other organisms, usually requiring higher concentrations of cefazolin. In 5 studies, mean cefazolin concentrations were higher than all of the MICs they reported for different pathogens/resistance patterns, ranging from 0.5 ug/mL for *S. aureus*, to 3--4 µg/mL for *E. coli* and Klebsiella species (4, 5, 8, 10, 11). 2 studies specifically reported the percentage of patients achieving bone concentrations higher than the MIC. Friedman et al. ([@CIT0018]) reported that 10 of 24 patients achieved bone concentrations higher than a MIC of 4 µg/mL at 30 minutes after administering 1g of cefazolin. Sharareh et al. ([@CIT0031]), using a MIC of 2 µg/mL, found that in the group receiving 1 g of cefazolin, 3 of 4 reached the MIC compared with 25 of 27 in the group receiving 2 g.

### Soft tissue concentrations {#s0011}

Cunha et al. ([@CIT0014]) took samples of the synovia of the knee and found mean peak levels of 8 mg/L, which cannot be compared with measurements in bone due to the unit (mg/L vs. ug/g) and absence of standard deviations ([Table 3](#t0003){ref-type="table"}, see [Supplementary data](https://doi.org/10.1080/17453674.2019.1577014)). Miller et al. ([@CIT0023]) found a mean cefazolin concentration of 11 µg/g in the soft tissue of the shoulder (SD not reported), which was lower than the 36 µg/g they found in bone at the same time-point. Young et al. ([@CIT0038]) found values between 7 µg/g and 13 µg/g in fat around the knee joint at different time-points, comparable to the values measured simultaneously in bone. Friedman et al. ([@CIT0018]), conversely, reported a higher percentage of patients with concentrations above the MIC (4 µg/g) in soft tissue than in bone of the knee at each time-point. Parsons et al. ([@CIT0028]) also found higher levels in the hip capsule than in bone with mean concentrations of 35 µg/g (SD 7.2) and 14 (2.3) respectively.

###### 

Soft tissue target site cefazolin concentrations

  Site Author (year)                                               n/dose   Time of sample min (SD)   Concentration µg/g (SD)
  ---------------------------------------------------------------- -------- ------------------------- -------------------------
  Hip capsule                                                                                          
   Parsons et al. ([@CIT0028])                                     6/4 g    64 (26)                   35 (24)
  Knee                                                                                                 
   Cunha et al. ([@CIT0014])                                       13/1 g   ND                        8 mg/L
   Friedman et al. ([@CIT0018])[^a^](#TF29){ref-type="table-fn"}   24/1 g   10                        75%
                                                                            30                        57%
                                                                            60                        54%
   Young et al. ([@CIT0038])                                       11/1 g   26 (23)                   11 (2.4)
  Shoulder                                                                                             
   Miller et al. ([@CIT0023])                                      7/1 g    40                        11

See [Table 3](#t0003){ref-type="table"}. ND = not data

Location of target site {#s0012}
-----------------------

Mean (peak) antibiotic concentrations for different measuring sites were ranging from 1.6 µg/g to 88 µg/g in the hip, from 0.64 µg/g to 40 µg/g in the knee, 2.4 µg/g in the foot, and 36 µg/g in the shoulder, measured at varying time-points. The results of each individual study are displayed in [Table 4--5](#t0004 t0005){ref-type="table"} and [Figure 5](#F0005){ref-type="fig"} (see [Supplementary data](https://doi.org/10.1080/17453674.2019.1577014)). [Figure 3](#F0003){ref-type="fig"} shows that although concentrations in the knee were lower than in the hip, nearly all measured concentrations were higher than the MIC of *S. aureus*. The concentrations that were lower or only just above the MIC were measured either more than 100 minutes after administration or in the foot. In 5 studies concentrations in the hip and knee were compared (2, 4, 10, 12, 13). All reported higher concentrations measured in the hip than in the knee, which were statistically significant in 2 (10, 12). The other 3 studies either did not compare knee and hip directly or did not perform statistical testing for this comparison.

![Mean target site concentrations organized according to location of measurements. Mean or maximum target site concentrations of all included studies. When results were reported separately for individual patients or results were given for multiple time-points, these are depicted separately. The bar with the dotted line represents the reported MIC90 of *Staphylococcus aureus* (0.5--2.0 µg/L).](IORT_A_1577014_F0003_C){#F0003}

###### 

Antibiotic concentrations organized by location of target site

  Author (year)                         Site         n/dose      Time of sample min (SD)   Concentration µg/g (SD)
  ------------------------------------- ------------ ----------- ------------------------- -------------------------
  Angthong et al. ([@CIT0003])          Hip          14/1 g      52 (7)                    22 (10)
                                        Hip          7/2 g       63 (23)                   40 (16)
  Bryan et al. ([@CIT0010])             Hip          31/1 g      118 (49)                  1.6 (1.4)
  Cunha et al. ([@CIT0013])             Hip          ND/1 g      40                        30
  Parsons et al. ([@CIT0028])           Hip**^b^**   6/4 g       61 (31)                   10 (2.9)
                                        Hip**^c^**   12/4 g      64 (26)                   14 (2.3)
                                        Hip**^d^**   3/4 g       37 (28)                   15 (3.3)
                                        Hip**^e^**   14/4 g      74 (30)                   88 (23)
  Polk et al. ([@CIT0030])              Hip          9/**^f^**   53 (20)                   7.7 (4.8)
  Sharareh et al. ([@CIT0031])          Hip          11/1&2 g    ND                        12 (6.7)
  Sorensen et al. (1978)                Hip          1/1 g       45                        12
  Williams et al. ([@CIT0036])          Hip          9/1 g       ND                        6.9 (1.3)
                                                     4/2 g       ND                        18
  Yamada et al. ([@CIT0037])            Hip          16/2 g      64 (33)                   32 (15)
  Bryan et al. ([@CIT0010])             Knee         11/1 g      107 (39)                  0.64 (0.57)
  Cunha et al. ([@CIT0014])             Knee         13/1 g      30                        11
  Friedman et al. ([@CIT0018])**^a^**   Knee         24/1 g      10                        20%
                                                                 30                        40%
                                                                 60                        39%
  Sharareh et al. ([@CIT0031])          Knee         20/1&2 g    ND                        6.0 (3.6)
  Williams et al. ([@CIT0036])          Knee         8/1 g       ND                        4.7 (2.4)
                                                     2/2 g       ND                        7.8
  Yamada et al. ([@CIT0037])            Knee         27/2 g      63 (19)                   16 (10)
  Young et al. ([@CIT0038])             Knee         11/1 g      34 (20)                   11 (2.5)
  Deacon et al. ([@CIT0015])            Foot         25/1 g      70                        2.4
  Miller et al. ([@CIT0023])            Shoulder     7/1 g       40                        36

Multiple samples, results are in percentage of patients achieving a

concentration \> 4 µg/g (MIC).

acetabulum,

proximal femur,

cortical shaft,

hip ground up

10 mg/kg

ND = not data

###### 

Antibiotic bone concentrations organized by dose

  Dose Author (year)                                          Site         n    Time of sample min (SD)   Concentration µg/g (SD)
  ----------------------------------------------------------- ------------ ---- ------------------------- -------------------------
  Cefazolin 1 g                                                                                            
  Angthong et al. ([@CIT0003])                                Hip          14   52 (7)                    22 (10)
  Bryan et al. ([@CIT0010])                                   Hip          31   118 (49)                  1.6 (1.4)
                                                              Knee         11   107 (39)                  0.64 (0.57)
  Cunha et al. ([@CIT0013])                                   Hip          ND   40                        30
  Cunha et al. ([@CIT0014])                                   Knee         13   30                        11
  Deacon et al. ([@CIT0015])                                  Foot         25   70                        2.4
  Friedman et al. ([@CIT0018])**^a^**                         Knee         24   10                        20%
                                                                                30                        40%
                                                                                60                        39%
  Miller et al. ([@CIT0023])                                  Shoulder     7    40                        36
  Sharareh et al. ([@CIT0031])                                H&K          4    ND                        5.0 (3.1)
  Sorensen et al. (1978)                                      Hip          1    45                        12
  Williams et al. ([@CIT0036])                                H&K          17   69                        5.9
  Young et al. ([@CIT0038])                                   Knee         11   34 (20)                   11 (2.5)
  Cefazolin 2 g                                                                                            
  Angthong et al. ([@CIT0003])                                Hip          7    63 (23)                   40 (16)
  Sharareh et al. ([@CIT0031])                                H&K          27   ND                        8.3 (5.6)
  Williams et al. ([@CIT0036])                                H&K          6    51                        15
  Yamada et al. ([@CIT0037])                                  H&K          42   63 (25)                   22 (15)
  Other dose                                                                                               
  Polk et al. ([@CIT0030])[^f^](#TF43){ref-type="table-fn"}   Hip          9    53 (20)                   7.7 (4.8)
  Parsons et al. ([@CIT0028]) **^g^**                         Hip**^b^**   6    61 (31)                   10 (2.9)
                                                              Hip**^c^**   12   64 (26)                   14 (2.3)
                                                              Hip**^d^**   3    37 (28)                   15 (3.3)
                                                              Hip**^e^**   14   74 (30)                   88 (23)

See [Table 3](#t0003){ref-type="table"}

acetabulum,

proximal femur,

cortical shaft,

hip ground up

10 mg/kg,

Cefazolin 4 g

H&K = Hip and knee

ND = not data

Of the 5 studies measuring antibiotic concentrations at different target sites, 4 (2, 10, 12, 13) could be pooled. The results from Cunha et al. ([@CIT0014]) could not be included in the meta-analysis due to the fact that no standard deviations were provided. When pooled, target site cefazolin concentrations were significantly higher in the hip (acetabulum, femoral head, or proximal femur) than in the knee (distal femur or proximal tibia) with a mean difference of 4 µg/g (CI 0.8--7) ([Figure 5](#F0005){ref-type="fig"}, see [Supplementary data](https://doi.org/10.1080/17453674.2019.1577014)). Although the time-points at which concentrations were measured differed between studies, the time-points of measurements in hip and knee within each study were similar. Heterogeneity between the studies is high, with an I2 of 83%.

Dose of cefazolin {#s0013}
-----------------

Bone concentrations were ranging from 0.64 µg/g to 36 µg/g when 1 g of cefazolin was given, 8.3 µg/g to 40 µg/g in 2 g, 10 µg/g to 88 µg/g in 4 g, and 7.7 µg/g in the study administering 10 mg/kg ([Figure 4](#F0004){ref-type="fig"}, [Table 5](#t0005){ref-type="table"} in [Supplementary data](https://doi.org/10.1080/17453674.2019.1577014)). 3 studies compared target-site concentrations according to the given dose of cefazolin (either 1 g or 2 g) (1, 10, 12). All of these studies report higher levels for the group receiving 2 g of cefazolin, but only in 1 study statistical significance was achieved (1) ([Figure 6](#F0006){ref-type="fig"}, see [Supplementary data](https://doi.org/10.1080/17453674.2019.1577014)). [Figure 4](#F0004){ref-type="fig"} shows that the concentrations lower or just above the MIC were all measured after administration of 1 g of cefazolin. Only 2 studies (1, 10) could be used for meta-analysis, because of missing standard deviations in the study by Williams et al. ([@CIT0036]). As shown in [Figure 6](#F0006){ref-type="fig"}, pooling the results did not lead to a statistically significant difference in target site concentration (mean difference --9, CI --23 to 4). Time-points of the measurements were similar both between and within the different studies. Nonetheless, heterogeneity between the studies was high with an I2 of 78%.

![Mean target site concentrations organized according to dose of cefazolin. Mean or maximum target site concentrations of all included studies. When results were reported separately for individual patients or results were given for multiple time points, these are depicted separately. The bar with the dotted line represents the reported MIC90 of *Staphylococcus aureus* (0.5--2.0 µg/L).](IORT_A_1577014_F0004_C){#F0004}

Discussion {#s0014}
==========

Because of the large clinical implications of SSIs in orthopedic trauma surgery, prophylactic antibiotics are widely initiated. However, dosage recommendations and corresponding efficacy remain unclear, partly because of the unequal distribution of drugs throughout the body. Sufficient concentrations of antibiotics at the target site (location of surgery) are required for optimal infection prevention. Therefore this meta-analysis focused on the target-site concentrations of cefazolin, the most commonly used prophylactic in orthopedic/trauma surgery.

A few limitations can be pointed out for this review and the available literature. First of all, the quality of the individual studies included in this systematic review varied. Most studies presented data that were collected before the year 2000, which often resulted in incomplete reporting and possibly outdated analysis methods. Also, given the fact that most studies included only elective orthopedic surgery, selection bias, by including only relatively healthy patients, may have occurred. Second, given the large heterogeneity in methods used for sampling, timing of the samples, processing, and analyzing, less than half of the results could be pooled. Third, target-site concentrations of an antibiotic may also be influenced by other patient or surgical characteristics such as renal function, obesity, bleeding, or tourniquet use. Although most of these characteristics do not seem to differ within study groups, tourniquet use could have an influence on the comparison between samples of hip and knee. Another limitation is the fact that all of the individual studies measured concentrations in samples of bone/soft tissue, the so called "whole tissue concentration." As described by Mouton et al. ([@CIT0026]), these concentrations are only an estimate of the "unbound" or active part of the drug and cannot be credibly compared with the MIC, which is the total (unbound plus plasma protein bound) concentration in serum. Moreover, homogenizing or grinding up whole-tissue samples leads to dilution of the drug by mixing intracellular and extracellular fluids, resulting in, depending on the type of drug, under- or overestimation of its concentrations (Mouton et al. [@CIT0026]). Nevertheless, simply using the serum concentration as a surrogate might not be sufficient for estimating effect, since the distribution of drugs throughout the body is not homogeneous (Müller et al. [@CIT0027]). Finally, regarding the clinical implications of antibiotic prophylaxis, more than the concentration itself, the time that the concentration is higher than the MIC (T \> MIC) is important. The T \> MIC should at least overlap with the "decisive period." This is the period that starts at incision and ends after 3 hours, during which antibiotics can effectively suppress the development of a wound infection (Burke [@CIT0011]). Instead of reporting this T \> MIC, all included studies solely measured antibiotic concentrations at individual moments in time. When samples are taken at multiple time-points, they can be used to predict levels of antibiotics in tissue over a course of time, using population kinetics, like Gergs et al. ([@CIT0019]). With population kinetics, model predicted time-concentration curves for each patient can be fabricated, which allows the evaluation of the T \> MIC, and therefore a more precise estimate of clinical efficacy.

We found a large variation in target site cefazolin concentrations of the extremity between different studies. In general, the achieved concentrations in bone surpassed the minimal inhibitory concentration (MIC) for *S. aureus*, the most common pathogen of an SSI. However, when stratifying the results on the location of the target site and dose of cefazolin, some measurements did not reach this MIC.

Regarding the association between location of the target site and antibiotic concentrations, our study showed that the same dosage of cefazolin resulted in statistically significantly lower concentrations in the knee than in the hip. Although, with just a single study in the foot (Deacon et al. [@CIT0015]), no definite conclusions can be drawn, this could mean that for surgery of the more distal parts of the extremity (e.g., foot/ankle), 1 g of cefazolin is not sufficient as prophylaxis. Whether or not a higher dose is beneficial in this area is yet to be determined.

As for the relationship between cefazolin dose and concentration, all 3 articles that compared different dosages found higher concentrations when 2 g was given instead of 1 g, although only 1 with statistical significance. A visualization of these concentrations, including also the studies investigating only one dose, suggests that the higher the dose, the higher the concentration ([Figure 4](#F0004){ref-type="fig"}). However, even though concentrations seemed increasingly high, the clinical implications of this phenomenon have not been investigated. A ceiling effect, where higher concentrations would not lead to fewer SSIs, is likely to occur at a certain time and could pave the way for antimicrobial resistance.

This first systematic review shows that there is a large variation in target site cefazolin concentrations of the extremity between different studies. In general, the achieved concentrations in bone surpassed the minimal inhibitory concentration (MIC) for *S. aureus*, the most common pathogen of an SSI. Most importantly, we found that the local concentration of cefazolin is associated with the location of the target site. Although no definite conclusions can be drawn based on this study, a higher dose of cefazolin seems to produce higher whole-tissue concentrations. These insights could be helpful on the path towards more efficient use of antibiotics. In particular, this study gives rise to the question whether the dose of prophylactic cefazolin needs to be adjusted to the location of the target site. To make any recommendations for the dose of prophylactic cefazolin in orthopedic/trauma surgery of the extremity however, additional prospective research is needed. We believe that a preclinical trial, comparing multiples dosages and locations of measurement in the extremity, is necessary before further investigating the efficacy of prophylactic cefazolin in preventing SSIs.

Supplementary data {#s0015}
==================

[Tables 3--5](#t0003 t0004 t0005){ref-type="table"} and [Figures 2](#F0002){ref-type="fig"} and [5--6](#F0005 F0006){ref-type="fig"} are available as [supplementary data](https://doi.org/10.1080/17453674.2019.1577014) in the online version of this article, <http://dx.doi.org/> 10.1080/17453674.2019.1577014

![Pooled results: mean target site concentrations compared by location of measurement.](IORT_A_1577014_F0005_C){#F0005}

![Pooled results: mean target site bone concentrations compared by dose. Due to the small number of studies for this outcome, no predictive interval was computed](IORT_A_1577014_F0006_C){#F0006}
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